En Es
Categories

Industry News

AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms

By Medimaging International staff writers
13 Jul 2021

Image: AI Diagnostic Tool Analyzes CT Scans to Spot Prostate Cancer Before Patients Have Symptoms (Photo courtesy of RMIT University)Researchers have developed a diagnostic tool that can spot prostate cancer before patients have any symptoms, using artificial intelligence to analyze Computed Tomography (CT) scans in just seconds.

Researchers at RMIT University (Melbourne, Australia), in collaboration with clinicians at St Vincent’s Hospital Melbourne (Australia), have developed an artificial intelligence (AI) program that could catch the prostate cancer earlier, allowing for incidental detection through routine CT scans. The technology works by analyzing CT scans for tell-tale signs of prostate cancer, something even a well-trained human eye struggles to do.

Prostate cancer is the most diagnosed cancer and is slow growing, usually detected incidentally due to which it can go undiagnosed for years. It was responsible for an estimated 12% of male cancer deaths in 2020. Early detection is the key to successful treatment but men often dodge the doctor, avoiding diagnosis tests until it’s too late. CT imaging is not suitable for regular cancer screening because of the high radiation doses involved. CT scans were great for detecting bone and joint problems but even radiologists struggled to spot prostate cancers on the images. The new AI solution can be used to run a cancer check whenever men have their abdomen or pelvis scanned for other issues.

For the study, the researchers studied CT scans of asymptomatic patients, with and without prostate cancer. The team trained the AI software to look for features of disease in a variety of scans and where exactly to look for them, avoiding the need to manually crop the images. The AI performed better than radiologists who viewed the same images, detecting cancerous growths in just seconds. What’s more, the AI improved with each scan, learning and adapting to read images from different machines to spot even the smallest irregularities. The technology can be applied at scale, potentially integrating with a variety of diagnostic imaging equipment like MRI and DEXA machines - pending further research.

“We’ve trained our software to see what the human eye can’t, with the aim of spotting prostate cancer through incidental detection,” said RMIT’s Dr. Ruwan Tennakoon. “It’s like training a sniffer dog – we can teach the AI to see things that we can't with our own eyes, in the same way a dog can smell things human noses can’t.”

Related Links:
RMIT University
St Vincent’s Hospital Melbourne




E-mail Print
FaceBook Twitter Google+ Linked in

Additional news

22 Sep 2021
Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System
Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.
Read More
17 Sep 2021
44th IHF World Hospital Congress Presents Over 60 Plenary Sessions and 200 Renowned Speakers Across Four-Day Event
The 44th World Hospital Congress organized by The International Hospital Federation (Geneva, Switzerland) will bring together more than 200 healthcare experts, leading industry thinkers, and best practice presenters at over 60 sessions around nursing leadership, humanizing technology, COVID-19 vaccination, the next global pandemic, etc.
Read More
17 Sep 2021
Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028
 The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising infectious diseases, technological developments, as well as increased knowledge and acceptance of tailored treatments.
Read More
15 Sep 2021
Certest Offers Sensitive, Useful and Cheap CE-IVD Multiplex Assay for Rapid Diagnosis of Atypical Pneumonia
CerTest Biotec (Zaragoza, Spain) has developed and validated the CE-IVD multiplex assay VIASURE C. pneumoniae, M. pneumoniae & L. pneumophila real time PCR kit for the detection of principal pathogens implicated in atypical pneumoniae.
Read More
15 Sep 2021
Mesa Laboratories to Acquire Molecular Diagnostics Tools Company Agena Bioscience
Mesa Laboratories, Inc. (Lakewood, CO, USA) has entered into a definitive agreement to acquire Agena Bioscience, Inc. (San Diego, CA, USA).
Read More
14 Sep 2021
Zoll Acquires Medical Device and Digital Health Company Itamar Medical
ZOLL Medical Corporation (Chelmsford, MA, USA), an Asahi Kasei company, has signed an agreement to acquire Itamar Medical Ltd. (Caesarea, Israel), a medical device and digital health company focused on the integration of sleep apnea diagnosis into the cardiac patient care pathway.
Read More
13 Sep 2021
Global Blood, Gas and Electrolyte Analyzers Market Projected to Reach Nearly USD 3.50 Billion by 2023
The global blood, gas and electrolyte analyzers market is projected to grow at a CAGR of 8.6% from more than USD 2.10 billion in 2016 to nearly USD 3.50 billion by the end of 2023, driven by rapid developments in the healthcare sector that are resulting in the implementation of technologies to help care providers and patients in treating diseases. For instance, hospitals are implementing technologies like AR and VR that can provide real-time simulation of human body that can help them understand the anomaly of patients. However, the need for blood, gas analyzers to achieve greater accuracy and the requirement of regular maintenance are expected to hinder market growth.
Read More
09 Sep 2021
Stryker Completes Acquisition of Medical Device Company Gauss Surgical
Stryker (Kalamazoo, MI, USA) has completed the acquisition of Gauss Surgical (Menlo Park, CA, USA), a medical device company that has developed Triton, an artificial intelligence-enabled platform for real-time monitoring of blood loss during surgery.
Read More
08 Sep 2021
Global In Vitro Diagnostics (IVD) Quality Control Market Projected to Reach USD 1.4 Billion by 2026
The global in vitro diagnostics (IVD) quality control market is projected to grow at a CAGR of 5.3% from USD 1.1 billion in 2021 to USD 1.4 billion by 2026, thanks to the significant role played by IVD testing in clinical decision-making.
Read More
Copyright © 2000-2021 TradeMed.com. All rights reserved. | Terms And Conditions